SOURCE: Medivation, Inc.

Medivation, Inc.

March 31, 2011 08:00 ET

Medivation Announces Participation in Leerink Swann Cancer Roundtable Conference

SAN FRANCISCO, CA--(Marketwire - March 31, 2011) - Medivation, Inc. (NASDAQ: MDVN) today announced that David Hung, M.D., president and chief executive officer, will present at the Leerink Swann Cancer Roundtable Conference on Thursday, April 7, at 11:40 a.m. Eastern Time and participate in a panel discussion on prostate cancer at 12:15 p.m. Eastern Time at the Roosevelt Hotel in New York.

During the corporate presentation, Dr. Hung will provide an overview of Medivation and its clinical development programs for MDV3100 for prostate cancer and dimebon (latrepirdine) for Alzheimer's and Huntington diseases.

A live audio webcast of the corporate presentation will be available on the "Events and Presentations" page of the "Investor Relations" section of the Company's website at A replay also will be available for 30 days following the live presentation.

About Medivation

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel small molecule drugs to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their caregivers. Together with its corporate partners Astellas and Pfizer, Medivation currently has investigational drugs in Phase 3 development to treat advanced prostate cancer, mild-to-moderate Alzheimer's disease and Huntington disease. For more information, please visit us at